The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcoma
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCA...
Purpose. A retrospective study of prognostic factors and treatment outcome of osteosarcoma (OS) duri...
Osteosarcoma is a challenging disease requiring multidisciplinary management in expert centers for o...
INTRODUCTION: The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective inte...
Malignant bone tumours in children are rare, accounting for approximately 5% of all childhood cancer...
Background: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and...
Purpose. To report the outcome of 37 patients with metastatic osteosarcoma entered into a large rand...
The purpose of the study was to calculate population-based survival rates for osteosarcoma (OS) and ...
International audienceIn the OS2006 study, patients younger than 18 years were treated with a methot...
International audienceBACKGROUND:In most countries, reference chemotherapy for osteosarcoma is MAP r...
Purpose: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skelet...
Aims: Chondrosarcoma, osteosarcoma and Ewing sarcoma form the majority of malignant primary tumours ...
Background: Four international study groups undertook a large study in resectable osteosarcoma, whic...
Purpose: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skelet...
Background: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCA...
Purpose. A retrospective study of prognostic factors and treatment outcome of osteosarcoma (OS) duri...
Osteosarcoma is a challenging disease requiring multidisciplinary management in expert centers for o...
INTRODUCTION: The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective inte...
Malignant bone tumours in children are rare, accounting for approximately 5% of all childhood cancer...
Background: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and...
Purpose. To report the outcome of 37 patients with metastatic osteosarcoma entered into a large rand...
The purpose of the study was to calculate population-based survival rates for osteosarcoma (OS) and ...
International audienceIn the OS2006 study, patients younger than 18 years were treated with a methot...
International audienceBACKGROUND:In most countries, reference chemotherapy for osteosarcoma is MAP r...
Purpose: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skelet...
Aims: Chondrosarcoma, osteosarcoma and Ewing sarcoma form the majority of malignant primary tumours ...
Background: Four international study groups undertook a large study in resectable osteosarcoma, whic...
Purpose: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skelet...
Background: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCA...
Purpose. A retrospective study of prognostic factors and treatment outcome of osteosarcoma (OS) duri...
Osteosarcoma is a challenging disease requiring multidisciplinary management in expert centers for o...